Patents for A61P 35 - Antineoplastic agents (221,099)
09/2004
09/07/2004US6787346 Kinase capable of site-specific phosphorylation of IκBα
09/07/2004US6787335 Polynucleotides and polypeptides which are diagnostic markers for mammary gland cancer.
09/07/2004US6787321 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
09/07/2004US6787161 Anti-cancer compounds
09/07/2004US6787141 Peptide having for fibrinogen fragment E activity, analogs, antibodies and uses thereof
09/07/2004CA2166898C Novel structural analogues of vitamin d
09/07/2004CA2102777C Novel compositions based on taxane class derivatives
09/07/2004CA2093770C Aspartic acid derivatives, their preparation and use
09/02/2004WO2004074502A2 A process of preparing imatinib
09/02/2004WO2004074484A1 Method of screening apoptosis-controlling agent
09/02/2004WO2004074445A2 Model for studying the role of genes in tumor resistance to chemotherapy
09/02/2004WO2004074437A2 Compositions and methods for cancer immunotherapy
09/02/2004WO2004074434A2 Methods and compositions for administering therapeutic and diagnostic agents
09/02/2004WO2004074324A2 Modulation of the poliovirus receptor function
09/02/2004WO2004074322A1 Modified soluble t cell receptor
09/02/2004WO2004074316A1 Conformationally constrained backbone cyclized peptide analogs
09/02/2004WO2004074309A1 Antitumoral d-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates
09/02/2004WO2004074307A1 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action
09/02/2004WO2004074295A1 Thiazole cycle polymers, process for producing the same, synthesis intermediates thereof and utilization of the same
09/02/2004WO2004074283A1 N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
09/02/2004WO2004074263A1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
09/02/2004WO2004074251A1 Derivatives of azasugars as anticancer agents
09/02/2004WO2004074248A2 Isolation and structure of cribrostatin 6
09/02/2004WO2004074244A2 Pyrimidine compounds
09/02/2004WO2004074236A1 Novel transcriptional factor, process for producing the same and use thereof
09/02/2004WO2004074218A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
09/02/2004WO2004073742A1 Degradation inhibitor for hepatitis b virus x interacting protein
09/02/2004WO2004073739A1 A method of diagnosis and treatment
09/02/2004WO2004073728A2 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components
09/02/2004WO2004073727A1 Method for improving qol and composition therefor
09/02/2004WO2004073725A1 Active ingredients preparation and single compound purification from traditional chinese herbal medicine fructus trichosanthis and uses thereof
09/02/2004WO2004073724A1 Endogenous pharmaceutical composition produced on the basis of an intentional activation of humoral mediators of the nerve endings of cerebral cortex
09/02/2004WO2004073722A1 Superoxide anion decomposing agent
09/02/2004WO2004073650A2 Peptidomimetic inhibitors of stat3 activity and their medical uses
09/02/2004WO2004073648A2 Composition and methods for inhibiting cell survival
09/02/2004WO2004073613A2 A medicine and food
09/02/2004WO2004073601A2 Process for the preparation of hexacyclic camptothecin derivatives
09/02/2004WO2004073595A2 Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use
09/02/2004WO2004073593A2 Use of acylated aminopropanediols and sulphur and nitrogen analogues of same for different therapeutic applications
09/02/2004WO2004073592A2 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier
09/02/2004WO2004073375A2 Podophyllotoxin derivatives as antitumor agents
09/02/2004WO2004062551A3 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
09/02/2004WO2004050057A3 An exopolysaccharides delivery system for active molecules
09/02/2004WO2004037187A3 Metal-containing materials, compositions and methods
09/02/2004WO2004026319A3 Pharmaceutical compositions increasing camp useful for the treatment of cancers
09/02/2004WO2004018000A3 Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
09/02/2004WO2004014851A3 Tyrosine kinase inhibitors
09/02/2004WO2004008137A3 Diagnosis and therapy of breast tumours resistant to antiestrogen treatment
09/02/2004WO2003101375A3 Immunostimulatory oligonucleotides and uses thereof
09/02/2004WO2003084344A3 Method of improving absorption of vitamin e by a pet animal
09/02/2004WO2003032906A3 Delivery of poorly soluble drugs
09/02/2004WO2003015697A3 Interleukin-2 mutants with reduced toxicity
09/02/2004WO2003000200A3 β-2'-OR 3'-HALONUCLEOSIDES
09/02/2004WO2002092589A3 Novel decalactones from associated fungi of marine sponges and their synthetic derivatives as medicaments
09/02/2004WO2002074289A3 Antitumor compositions containing taxane derivatives
09/02/2004WO2002072766A8 Induction of tumor immunity by variants of folate binding protein
09/02/2004US20040171848 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
09/02/2004US20040171844 Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase
09/02/2004US20040171839 Serine protease inhibitor; therapy for thrombosis , cardiovascular disorders
09/02/2004US20040171825 Human fibroblast growth factor-related compositions
09/02/2004US20040171806 Modified hpv e6 and e7 genes and proteins useful for vaccination
09/02/2004US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits
09/02/2004US20040171668 Reducing side effects, lowering neurotoxicity; longer lasting antitumor action
09/02/2004US20040171658 Blood coagulation factor Xa inhibition; such as 2-O-(3'-amidinobenzyl)-5-O-(3''-amidinophenyl)-1,4:3,6-dianhydrosorbitol
09/02/2004US20040171639 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists
09/02/2004US20040171630 both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases,
09/02/2004US20040171618 Compounds as PDE IV and TNF-inhibitors
09/02/2004US20040171617 treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer
09/02/2004US20040171616 preventing and treating thrombotic conditions, such as coronary artery disease, cerebrovascular disease, and other coagulation related disorders
09/02/2004US20040171608 Synthesis of clasto-lactacystin beta-lactone and analogs thereof
09/02/2004US20040171592 reduced gastric effects; salicylic acid derivatives
09/02/2004US20040171590 Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
09/02/2004US20040171581 Polysaccharidic esters of retinoic acid
09/02/2004US20040171557 treating or educating said cells ex vivo in the presence of: intermediary metabolite; antigens or epitopes associated with said disease, or the immune-mediated inflammatory response; re-administering to said subject said treated or educated cells
09/02/2004US20040171549 Method of inhibiting angiogenesis or invasion or formation of metastases
09/02/2004US20040171546 Regulation of lung tissue by hedgehog-like polypeptides and formulations and uses related thereto
09/02/2004US20040171530 Polypeptides containing cysteine and tryptophan
09/02/2004US20040171528 Raise intracellular or extracellular or serum level of metabolite in subject
09/02/2004US20040171527 Regulation of immune responses by manipulation of intermediary metabolite levels
09/02/2004US20040171526 Raise intracellular or extracellular or serum level of metabolite in subject
09/02/2004US20040171522 Raise the intracellular or extracellular or serum level of metabolite in subject
09/02/2004US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin
09/02/2004US20040171111 Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof
09/02/2004US20040171090 Screening for cytotoxic t-lymphocyte recognition antigen associated with human t-cell leukemia virus infected cells for diagnosing and prognosing inflammation and cell proliferation disorders
09/02/2004US20040171066 Template-fixed peptidomimetics with antimicrobial activity
09/02/2004US20040171012 Nucleic acid-associated proteins
09/02/2004US20040171003 Using oligonucleotide probes to generate gene expression profile of tumor marker proteins for use in diagnosis of cell proliferative disorders
09/02/2004US20040170999 Nuclear hormone receptor ligand binding domain
09/02/2004US20040170997 used in drug screening for preventing or treating diseases associated with abnormalities in intracellular signal transduction; genetic engineering
09/02/2004US20040170980 Molecules capable of binding to telomere and the like and method with the use of the same
09/02/2004US20040170969 GRF2 binding proteins and applications thereof
09/02/2004US20040170961 for drug screening anticancer agents; solid phase synthesis; animal models; genetic engineering; kits
09/02/2004US20040170713 To promote good health and as a dietary additive
09/02/2004US20040170704 Process for the manufacture of a herbal composition
09/02/2004US20040170678 Liposomal antineoplastic drugs and uses thereof
09/02/2004US20040170653 recognised by CD8-positive cytotoxic T-lymphocytes as a peptide antigen and causes a CTL-induced lysis and/or apoptosis of tumor or leukemia cell; has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto-oncoprotein
09/02/2004US20040170644 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
09/02/2004US20040170632 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
09/02/2004US20040170620 Selected antibody compositions for binding to aminophospholipids
09/02/2004US20040170610 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation